Mylan receives tentative FDA approval for generic acid reflux tablets

By Angela McDaniels

Seattle, Jan. 19 - Mylan Pharmaceuticals Inc. said the Food and Drug Administration has granted tentative approval for the company's Rabeprazole sodium delayed-release tablets, 20 mg.

The drug is the generic version of Eisai Medical Research Inc.'s Aciphex tablets, which are used to treat acid reflux disease.

Annual U.S. sales of Aciphex were $1.3 billion as of June 2005, the company said.

Mylan is a pharmaceutical company based in Pittsburgh that develops, licenses, manufactures and markets generic and proprietary products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.